Antimicrobial Industry News in Europe
The European antimicrobial industry in 2026 is advancing along three core themes: regulatory tightening, antimicrobial resistance (AMR) prevention, and domestic supply chain strengthening. The Biocidal Products Regulation (BPR) and REACH regulations on nanomaterials continue to be updated, while demand for antimicrobial textiles, construction adhesives, medical materials and other application areas maintains steady growth. Key industry updates and developments are as follows:
I. Regulatory Policy and Approval Updates
1. Intensive BPR approval updates with changes to regulatory status of multiple active substances
In August 2026, the European Union issued Commission Implementing Regulation (EU) 2026/1410, formally authorizing the "Prisman Händedesinfektion" series of hand disinfection biocidal products for placement on the EU market, with an authorization valid until 30 September 2035.
In March 2026, the EU issued Decision (EU) 2026/619, extending the approval period of copper(II) oxide as a biocidal active substance for product-type 8 (PT 8) from July 2026 to 31 July 2029, reserving time for the full renewal assessment of this inorganic antimicrobial active substance.
In August 2026, the EU notified the WTO of multiple draft biocidal review proposals: it plans to approve the renewal of hydrochloric acid for PT 2 (public health disinfectant) products; meanwhile, it proposes not to renew medetomidine, not to approve DMDMH, and to reject the use of hydrogen peroxide, alkyl dimethyl benzyl ammonium chloride (ADBAC C12-C14) and electrolytically generated active bromine in specific product categories.
In April 2026, the EU authorized the "ECA Disinfect skin Product family 7" skin disinfection product, with active chlorine released from hypochlorous acid as the active ingredient, valid until March 2036.
2. REACH rules for nano antimicrobials continue to tighten, forcing industry process transformation
Driven by strict restrictions on nano-particle emissions under Annex XVII of the EU REACH Regulation, the number of European antimicrobial finishing manufacturers dropped from 47 to 29 between 2022 and 2025. The regulation is pushing the industry to shift from "leachable nano-coating finishing" to polymer-bonded masterbatch solutions. Both silver-based and zinc oxide-based nano antimicrobials must meet low-leaching and traceability compliance requirements, and the market space for free-type nano finishing agents continues to narrow.
3. Upgraded AMR control covering the entire pharmaceutical and veterinary chain
In May 2026, the EU updated the list of third-country animal-derived product export access, requiring exporting countries to strictly comply with EU animal antimicrobial regulations – prohibiting the use of antimicrobials for growth promotion purposes and banning antimicrobials critical for human clinical use. The new regulation entered into force on 3 September 2026.
In September 2026, the EU's "Pharmaceutical Package" launched new incentive policies to reward the R&D of new antibiotics through a transferable exclusivity voucher system, accelerating the market launch of products addressing antimicrobial resistance.
In May 2026, the European Parliament and the Council reached an agreement on the supply of key medicines, including antibiotics in the key guaranteed category, and reducing external supply chain dependence through investment in domestic production capacity and a "Buy European" procurement strategy.
II. Industry Market and Industrial Trends
1. Europe remains the world's largest antimicrobial textile market
Europe accounted for 35.01% of global antimicrobial textile market revenue in 2025, making it the largest regional market worldwide. The global market is projected to grow at a CAGR of 3.84% from 2026 to 2031, while the European market continues to grow driven by compliance demand in the medical, home textile and workwear sectors:
Germany: Promoting large-scale application of masterbatch antimicrobial solutions based on online metering technology from equipment manufacturers such as Oerlikon.
UK: NHS medical washing standards drive growing demand for antimicrobial dressings and surgical packs.
France: Medical antimicrobial dressings require MDR CE certification, with the market concentrating on leading enterprises.
Italy: The Prato textile district is shifting to polyester-cotton blended antimicrobial solutions to reduce finishing loss of traditional wool fabrics.
2. Rising demand for inorganic antimicrobials in construction materials and adhesives
As the EU tightens restrictions on organic anti-mold agents, the application share of inorganic antibacterial and anti-mold agents such as nano zinc oxide and copper oxide in kitchen and bathroom silicone sealants, tile grouts and construction sealants continues to rise. Compared with traditional organic anti-mold agents, inorganic systems offer better leaching resistance, weather resistance and long-term performance, meeting the environmental and durability requirements of EU construction products, and have become the mainstream choice for material functional upgrading.
III. Technology R&D and Product Innovation
Novel anti-resistant antibiotic enters clinical stage In March 2026, Swiss pharmaceutical company Basilea initiated Phase I human clinical trials of its novel antibiotic BAL2420 (an LptA inhibitor). Targeting Gram-negative bacteria of the Enterobacteriaceae family (including carbapenem- and colistin-resistant strains), the product is listed by the WHO as a priority antimicrobial target, and the project is funded by the global CARB-X fund.
EU's first GMP-grade therapeutic phage production qualification awarded in France In May 2026, the Hospices Civils de Lyon (HCL) became the first public institution in the EU to obtain GMP authorization for the production of human-use therapeutic phages. Phage therapy, as an alternative to antibiotics, is mainly used for the treatment of multidrug-resistant bacterial infections, marking the transition of new antimicrobial technologies in the EU from R&D to industrialization.
IV. Implications for Relevant Export Enterprises
Textile antimicrobials: Focus should be placed on REACH nano-leaching restrictions. Priority should be given to recommending masterbatch and chemically bonded solutions to avoid compliance risks of free nano products.
Antibacterial and anti-mold agents for adhesives/sealants: Organic anti-mold agents face more approval rejections, while inorganic categories such as nano zinc oxide and copper oxide continue to gain market share. However, compliance registration of active substances must be completed in accordance with BPR regulations.
All antimicrobial products exported to the EU must align their formulations and labeling with the latest BPR, REACH and MDR regulations, and complete preliminary trials and compliance assessments in advance.